Aktuelle smitsomme sygdomme
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#102134
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#101319
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#100523
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#99820
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#99553
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#98905
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#98417
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#96575
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#96221
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#96223
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#96012
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#95746
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#95119
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#94847
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#94792
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#94040
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#93813
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#93814
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#93648
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#93245
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#92956
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#92305
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#92265
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#92235
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#92222
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#90607
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#90369
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#90116
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#89860
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#89577
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#89429
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
https://www.infmed.dk/udbrud?rss_filter=omicron&setpoint=88329#88329
Søgeord (omicron) valgt.
32 emner vises.
Morbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes the duration of protection provided by the original monovalent COVID-19 vaccines.
Læs mereCharlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mereAnne J Huiberts, Christina E Hoeve, Brechje de Gier, Jeroen Cremer, Bas van der Veer, Hester E de Melker, Janneke HHM van de Wijgert, Susan van den Hof, Dirk Eggink and Mirjam J Knol
Eurosurveillance latest updates, 8.03.2024
Tilføjet 8.03.2024
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).
Læs mereNita Perumal, Viktoria Schönfeld and Ole Wichmann
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
Læs mereDanuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).
Læs mereMorbidity and Mortality Weekly Report (MMWR), 2.02.2024
Tilføjet 2.02.2024
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.
Læs mereLiliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mereAnastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mereAngela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mereBette Liu, Sandrine Stepien, Ketaki Sharma and Kristine Macartney
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
We followed 4,081,257 Australian adults aged ≥ 65 years between November 2022 and May 2023 for COVID-19-specific mortality, when recombinant SARS-CoV-2 Omicron lineages (predominantly XB and XBB) as well as BA.2.75 were circulating. Compared with a COVID-19 booster targeting ancestral SARS-CoV-2 given > 180 days earlier, the relative vaccine effectiveness against COVID-19 death of a bivalent (ancestral/BA.1 or ancestral/BA.4-5) booster given 8 to 90 days earlier was 66.0% (95%CI: 57.6 to 72.2%) and that of a monovalent ancestral booster given 8 to 90 days earlier was 44.7% (95%CI: 23.9 to 59.7%).
Læs mereCarmen Espinosa-Gongora, Carlo Berg, Moa Rehn, Javier Edo Varg, Lena Dillner, Neus Latorre-Margalef, Anna J Székely, Emmi Andersson and Elin Movert
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
The SARS-CoV-2 BA.2.86 Omicron subvariant was first detected in wastewater in Sweden in week 31 2023, using 21 highly specific markers from the 50 investigated. We report BA.2.86’s introduction and subsequent spread to all 14 regions performing wastewater sampling, and on 70 confirmed COVID-19 cases, along with the emergence of sublineages JN.1 and JN.2. Further, we investigated two novel mutations defining the unique BA.2.86 branching in Sweden. Our integrated approach enabled variant tracking, offering evidence for well-informed public health interventions.
Læs mereChristoph Rudin, Nena Bollen, Samuel L Hong, Fanny Wegner, Lida Politi, Kassiani Mellou, Caspar Geenen, Sarah Gorissen, Bruno Verhasselt, Keith Durkin, Coralie Henin, Anne-Sophie Logist, Simon Dellicour, Tobias Resa, Tanja Stadler, Piet Maes, Lize Cuypers, Emmanuel André, Adrian Egli and Guy Baele
Eurosurveillance latest updates, 10.11.2023
Tilføjet 10.11.2023
BackgroundThe earliest recognised infections by the SARS-CoV-2 Omicron variant (Pango lineage B.1.1.529) in Belgium and Switzerland suggested a connection to an international water polo tournament, held 12–14 November 2021 in Brno, Czechia. AimTo study the arrival and subsequent spread of the Omicron variant in Belgium and Switzerland, and understand the overall importance of this international sporting event on the number of infections in the two countries. MethodsWe performed intensive forward and backward contact tracing in both countries, supplemented by phylogenetic investigations using virus sequences of the suspected infection chain archived in public databases. ResultsThrough contact tracing, we identified two and one infected athletes of the Belgian and Swiss water polo teams, respectively, and subsequently also three athletes from Germany. In Belgium and Switzerland, four and three secondary infections, and three and one confirmed tertiary infections were identified. Phylogenetic investigation demonstrated that this sporting event played a role as the source of infection, but without a direct link with infections from South Africa and not as a superspreading event; the virus was found to already be circulating at that time in the countries involved. ConclusionThe SARS-CoV-2 Omicron variant started to circulate in Europe several weeks before its identification in South Africa on 24 November 2021. Accordingly, it can be assumed that travel restrictions are usually implemented too late to prevent the spread of newly detected SARS-CoV-2 variants to other regions. Phylogenetic analysis may modify the perception of an apparently clear result of intensive contact tracing.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 26.10.2023
Tilføjet 26.10.2023
CDC detected BA.2.86 variant in a traveler within days of being reported. Timely detection provides early warning of new COVID-19 variants entering the U.S.
Læs mereECDC
ECDC COVID-19 updates, 19.10.2023
Tilføjet 19.10.2023
This report is based on the findings from two focused After-Action reviews (AARs) in Norway and Georgia that discussed the use of evidence in the advice-making process for long-term care facilities (LTCFs) during the start of the COVID-19 Omicron wave in early 2022.
Læs mereECDC
ECDC COVID-19 updates, 17.10.2023
Tilføjet 17.10.2023
Report from the after-action review (AAR) in Norway during the emergence of the Omicron variant of concern of SARS-CoV-2.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 29.09.2023
Tilføjet 29.09.2023
This report describes how young infants of people who received a COVID-19 vaccine while pregnant were less likely to be hospitalized or experience serious complications from COVID-19.
Læs mereKamille Fogh, Tine Graakjær Larsen, Cyril Jean-Marie Martel, Frederik Trier Møller, Lasse Skafte Vestergaard, Ramona Trebbien, Anne-Marie Vangsted and Tyra Grove Krause
Eurosurveillance latest updates, 22.09.2023
Tilføjet 22.09.2023
BackgroundDuring the COVID-19 pandemic, the Danish National Institute for Infectious Disease, Statens Serum Institute (SSI) developed a home-based SARS-CoV-2 surveillance system. AimsWe wanted to determine whether a cohort of individuals performing self-administered swabs for PCR at home could support surveillance of SARS-CoV-2, including detection and assessment of new variants. We also aimed to evaluate the logistical setup. MethodsFrom May to July 2022, 10,000 blood donors were invited to participate, along with their household members. Participation required performing a self-swab for 4 consecutive weeks and answering symptom questionnaires via a web app. Swabs were sent by post to SSI for PCR analysis and whole genome sequencing. After study completion, participants were asked to complete a questionnaire concerning their experience. ResultsIn total, 2,186 individuals enrolled (47.4% blood donors), and 1,333 performed self-swabbing (53.0 blood donors), of whom 48 had at least one SARS-CoV-2-positive sample. Fourteen different Omicron subvariants, primarily BA.5 subvariants, were identified by whole genome sequencing (WGS). In total, 29 of the 63 SARS-CoV-2-positive samples were taken from individuals who were asymptomatic at the time of swabbing. Participants collected 2.9 swabs on average, with varying intervals between swabs. Transmission within households was observed in only three of 25 households. ConclusionParticipants successfully performed self-swabs and answered symptom questionnaires. Also, WGS analysis of samples was possible. The system can support surveillance of respiratory pathogens and also holds potential as a diagnostic tool, easing access to test for at-risk groups, while also reducing the burden on healthcare system resources.
Læs mereTomáš Kliegr, Jiří Jarkovský, Helena Jiřincová, Jaroslav Kuchař, Tomáš Karel, David Chudán, Stanislav Vojíř, Michal Zavřel, Ondřej Šanca and Ruth Tachezy
Eurosurveillance latest updates, 22.09.2023
Tilføjet 22.09.2023
BackgroundThe sensitivity and specificity of selected antigen detection rapid diagnostic tests (AG-RDTs) for SARS-CoV-2 were determined in the unvaccinated population when the Delta variant was circulating. Viral loads, dynamics, symptoms and tissue tropism differ between Omicron and Delta. AimWe aimed to compare AG-RDT sensitivity and specificity in selected subgroups during Omicron vs Delta circulation. MethodsWe retrospectively paired AG-RDT results with PCRs registered in Czechia’s Information System for Infectious Diseases from 1 to 25 December 2021 (Delta, n = 20,121) and 20 January to 24 February 2022 (Omicron, n = 47,104). ResultsWhen confirmatory PCR was conducted on the same day as AG-RDT as a proxy for antigen testing close to peak viral load, the average sensitivity for Delta was 80.4% and for Omicron 81.4% (p
Læs mereMedscape Infectious Diseases, 20.09.2023
Tilføjet 20.09.2023
The American College of Physicians has issued an updated version of its living, rapid practice point guideline on the best treatment options for outpatients with confirmed COVID-19. MDedge News
Læs mereTommy Nyberg, Peter Bager, Ingrid Bech Svalgaard, Dritan Bejko, Nick Bundle, Josie Evans, Tyra Grove Krause, Jim McMenamin, Joël Mossong, Heather Mutch, Ajibola Omokanye, André Peralta-Santos, Pedro Pinto-Leite, Jostein Starrfelt, Simon Thelwall, Lamprini Veneti, Robert Whittaker, John Wood, Richard Pebody and Anne M Presanis
Eurosurveillance latest updates, 8.09.2023
Tilføjet 8.09.2023
Several SARS-CoV-2 variants that evolved during the COVID-19 pandemic have appeared to differ in severity, based on analyses of single-country datasets. With decreased testing and sequencing, international collaborative studies will become increasingly important for timely assessment of the severity of new variants. Therefore, a joint WHO Regional Office for Europe and ECDC working group was formed to produce and pilot a standardised study protocol to estimate relative case-severity of SARS-CoV-2 variants during periods when two variants were co-circulating. The study protocol and its associated statistical analysis code was applied by investigators in Denmark, England, Luxembourg, Norway, Portugal and Scotland to assess the severity of cases with the Omicron BA.1 virus variant relative to Delta. After pooling estimates using meta-analysis methods (random effects estimates), the risk of hospital admission (adjusted hazard ratio (aHR) = 0.41; 95% confidence interval (CI): 0.31−0.54), admission to intensive care unit (aHR = 0.12; 95% CI: 0.05−0.27) and death (aHR = 0.31; 95% CI: 0.28−0.35) was lower for Omicron BA.1 compared with Delta cases. The aHRs varied by age group and vaccination status. In conclusion, this study demonstrates the feasibility of conducting variant severity analyses in a multinational collaborative framework and adds evidence for the reduced severity of the Omicron BA.1 variant.
Læs mereMedscape Infectious Diseases, 1.09.2023
Tilføjet 1.09.2023
BA 2.86 is a subvariant of Omicron, but according to reports from the CDC, the strain has many more mutations than the ones that came before it. WebMD Health News
Læs mereMedscape Infectious Diseases, 14.08.2023
Tilføjet 14.08.2023
Most Canadians now have hybrid immunity against SARS-CoV-2 through a combination of infection and vaccination, but certain groups remain vulnerable. Medscape Medical News
Læs mereMedscape Infectious Diseases, 12.08.2023
Tilføjet 12.08.2023
Since April, a new COVID variant has cropped up. According to recent CDC data, EG.5 — from the Omicron family — now makes up 17% of all cases in the US, up from 7.5% in the first week of July. WebMD Health News
Læs mereMassimo Fabiani, Alberto Mateo-Urdiales, Chiara Sacco, Maria Cristina Rota, Emmanouil Alexandros Fotakis, Daniele Petrone, Martina Del Manso, Andrea Siddu, Paola Stefanelli, Antonino Bella, Flavia Riccardo, Giovanni Rezza, Anna Teresa Palamara, Silvio Brusaferro, Patrizio Pezzotti and on behalf of the Italian Integrated Surveillance of COVID-19 study group and of the Italian COVID-19 Vaccines Registry group
Eurosurveillance latest updates, 11.08.2023
Tilføjet 11.08.2023
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 11.08.2023
Tilføjet 11.08.2023
This report describes rates of SARS-CoV-2 infection and COVID-19 related deaths were higher among maintenance dialysis patients compared to rates in the U.S. population.
Læs mereToon Braeye, Joris A F van Loenhout, Ruben Brondeel, Veerle Stouten, Pierre Hubin, Matthieu Billuart, Pui Yan Jenny Chung, Mathil Vandromme, Chloé Wyndham-Thomas, Koen Blot and Lucy Catteau
Eurosurveillance latest updates, 30.06.2023
Tilføjet 30.06.2023
BackgroundThe Belgian COVID-19 vaccination campaign aimed to reduce disease spread and severity. AimWe estimated SARS-CoV-2 variant-specific vaccine effectiveness against symptomatic infection (VEi) and hospitalisation (VEh), given time since vaccination and prior infection. MethodsNationwide healthcare records from July 2021 to May 2022 on testing and vaccination were combined with a clinical hospital survey. We used a test-negative design and proportional hazard regression to estimate VEi and VEh, controlling for prior infection, time since vaccination, age, sex, residence and calendar week of sampling. ResultsWe included 1,932,546 symptomatic individuals, of whom 734,115 tested positive. VEi against Delta waned from an initial estimate of 80% (95% confidence interval (CI): 80–81) to 55% (95% CI: 54–55) 100–150 days after the primary vaccination course. Booster vaccination increased initial VEi to 85% (95% CI: 84–85). Against Omicron, an initial VEi of 33% (95% CI: 30–36) waned to 17% (95% CI: 15–18), while booster vaccination increased VEi to 50% (95% CI: 49–50), which waned to 20% (95% CI: 19–21) 100–150 days after vaccination. Initial VEh for booster vaccination decreased from 96% (95% CI: 95–96) against Delta to 87% (95% CI: 86–89) against Omicron. VEh against Omicron waned to 73% (95% CI: 71–75) 100–150 days after booster vaccination. While recent prior infections conferred higher protection, infections occurring before 2021 remained associated with significant risk reduction against symptomatic infection. Vaccination and prior infection outperformed vaccination or prior infection only. ConclusionWe report waning and a significant decrease in VEi and VEh from Delta to Omicron-dominant periods. Booster vaccination and prior infection attenuated these effects.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 23.06.2023
Tilføjet 23.06.2023
This report describes an increase in COVID-19 cases as new Omicron lineages became predominant.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 16.06.2023
Tilføjet 16.06.2023
This report describes how multiple omicron lineages were identified using genomic surveillance.
Læs mereMelissa Brady, Roisin Duffy, Lisa Domegan, Abigail Salmon, Binita Maharjan, Cathal O'Broin, Charlene Bennett, James Christle, Jeff Connell, Laura Feeney, Nadra Nurdin, Patrick Mallon, Peter Doran, Rosa McNamara, Sarah O'Grady, Sinead McDermott, Naomi Petty-Saphon and Joan O’Donnell
Eurosurveillance latest updates, 9.06.2023
Tilføjet 9.06.2023
BackgroundIn 2020, due to the COVID-19 pandemic, the European Centre for Disease Prevention and Control (ECDC) accelerated development of European-level severe acute respiratory infection (SARI) surveillance. AimWe aimed to establish SARI surveillance in one Irish hospital as part of a European network E-SARI-NET. MethodsWe used routine emergency department records to identify cases in one adult acute hospital. The SARI case definition was adapted from the ECDC clinical criteria for a possible COVID-19 case. Clinical data were collected using an online questionnaire. Cases were tested for SARS-CoV-2, influenza and respiratory syncytial virus (RSV), including whole genome sequencing (WGS) on SARS-CoV-2 RNA-positive samples and viral characterisation/sequencing on influenza RNA-positive samples. Descriptive analysis was conducted for SARI cases hospitalised between July 2021 and April 2022. ResultsOverall, we identified 437 SARI cases, the incidence ranged from two to 28 cases per week (0.7–9.2/100,000 hospital catchment population). Of 431 cases tested for SARS-CoV-2 RNA, 226 (52%) were positive. Of 349 (80%) cases tested for influenza and RSV RNA, 15 (4.3%) were positive for influenza and eight (2.3%) for RSV. Using WGS, we identified Delta- and Omicron-dominant periods. The resource-intensive nature of manual clinical data collection, specimen management and laboratory supply shortages for influenza and RSV testing were challenging. ConclusionWe successfully established SARI surveillance as part of E-SARI-NET. Expansion to additional sentinel sites is planned following formal evaluation of the existing system. SARI surveillance requires multidisciplinary collaboration, automated data collection where possible, and dedicated personnel resources, including for specimen management.
Læs mereGwenola Picard, Lucie Fournier, Anna Maisa, Claire Grolhier, Souhaila Chent, Caroline Huchet-Kervalla, Jeanne Sudour, Maël Pretet, Laurence Josset, Sylvie Behillil, Justine Schaeffer, Laboratory group and COVID-19 Investigation Group
Eurosurveillance latest updates, 2.06.2023
Tilføjet 2.06.2023
BackgroundSuccessive epidemic waves of COVID-19 illustrated the potential of SARS-CoV-2 variants to reshape the pandemic. Detecting and characterising emerging variants is essential to evaluate their public health impact and guide implementation of adapted control measures. AimTo describe the detection of emerging variant, B.1.640, in France through genomic surveillance and present investigations performed to inform public health decisions. MethodsIdentification and monitoring of SARS-CoV-2 variant B.1.640 was achieved through the French genomic surveillance system, producing 1,009 sequences. Additional investigation of 272 B.1.640-infected cases was performed between October 2021 and January 2022 using a standardised questionnaire and comparing with Omicron variant-infected cases. ResultsB.1.640 was identified in early October 2021 in a school cluster in Bretagne, later spreading throughout France. B.1.640 was detected at low levels at the end of SARS-CoV-2 Delta variant’s dominance and progressively disappeared after the emergence of the Omicron (BA.1) variant. A high proportion of investigated B.1.640 cases were children aged under 14 (14%) and people over 60 (27%) years, because of large clusters in these age groups. B.1.640 cases reported previous SARS-CoV-2 infection (4%), anosmia (32%) and ageusia (34%), consistent with data on pre-Omicron SARS-CoV-2 variants. Eight percent of investigated B.1.640 cases were hospitalised, with an overrepresentation of individuals aged over 60 years and with risk factors. ConclusionEven though B.1.640 did not outcompete the Delta variant, its importation and continuous low-level spread raised concerns regarding its public health impact. The investigations informed public health decisions during the time that B.1.640 was circulating.
Læs mereMedscape Infectious Diseases, 31.05.2023
Tilføjet 31.05.2023
The research team evaluated data from 8646 adults who had COVID-19 at different times during the pandemic and from 1118 persons who had not had COVID. WebMD Health News
Læs mereOlivier Supplisson, Tiffany Charmet, Simon Galmiche, Laura Schaeffer, Olivia Chény, Anne Lévy, Nathan Jeandet, Faïza Omar, Christophe David, Alexandra Mailles and Arnaud Fontanet
Eurosurveillance latest updates, 5.05.2023
Tilføjet 5.05.2023
BackgroundFollowing the SARS-CoV-2 Omicron variant spread, the use of unsupervised antigenic rapid diagnostic tests (self-tests) increased. AimThis study aimed to measure self-test uptake and factors associated with self-testing. MethodsIn this cross-sectional study from 20 January to 2 May 2022, the case series from a case–control study on factors associated with SARS-CoV-2 infection were used to analyse self-testing habits in France. A multivariable quasi-Poisson regression was used to explore the variables associated with self-testing among symptomatic cases who were not contacts of another infected individual. The control series from the same study was used as a proxy for the self-test background rate in the non-infected population of France. ResultsDuring the study period, 179,165 cases who tested positive through supervised tests were recruited. Of these, 64.7% had performed a self-test in the 3 days preceding this supervised test, of which 79,038 (68.2%) were positive. The most frequently reported reason for self-testing was the presence of symptoms (64.6%). Among symptomatic cases who were not aware of being contacts of another case, self-testing was positively associated with being female, higher education, household size, being a teacher and negatively associated with older age, not French by birth, healthcare-related work and immunosuppression. Among the control series, 12% self-tested during the 8 days preceding questionnaire filling, with temporal heterogeneity. ConclusionThe analysis showed high self-test uptake in France with some inequalities which must be addressed through education and facilitated access (cost and availability) for making it a more efficient epidemic control tool.
Læs mere